Michael W. Fried, MD is Professor of Medicine and Director of Hepatology at the University of North Carolina (UNC) at Chapel Hill. Dr. Fried completed his internship and residency in internal medicine at the State University of New York (SUNY) Health Science Center at Syracuse, where he also completed a fellowship in gastroenterology.
From 1990 to 1993, while serving as Medical Staff Fellow in the Liver Diseases Section at the National Institutes of Health (NIH) in Bethesda, Maryland, Dr. Fried performed clinical and laboratory studies of viral hepatitis. During his tenure at UNC, he has been the principal investigator on numerous clinical trials of antiviral agents for chronic hepatitis B and hepatitis C. Dr. Fried has been awarded continuous NIH extramural funding for over 15 years as principal investigator on several NIH cooperative clinical trials and he currently serves as the co-chair of the Hepatitis B Research Network (NIDDK). Dr. Fried was the recipient of an NIH career development award, which allowed him to provide mentorship to junior investigators in hepatitis research. Most recently, Dr. Fried is co-principal investigator of the HCV-TARGET international network studying HCV therapies used in usual clinical practice and co-PI of PRIORITIZE, a pragmatic clinical trial of HCV therapeutics.
Dr. Fried is the primary author or co-author on over 150 original publications, reviews, and book chapters concentrated in the field of viral hepatitis. He was inducted into the American Society of Clinical Investigation (ASCI), an honor society for clinical investigators.
Conflict of Interest
Dr. Michael W. Fried provides unpaid scientific consulting for AbbVie, Bristol-Myers Squibb, Merck and TARGET PharmaSolutions. He has received research grants paid to his institution from AbbVie, Bristol-Myers Squibb, Gilead, Merck and NIH. Stock in TARGET PharmaSolutions is held in an independently managed trust.